Search

Your search keyword '"Eric Deconninck"' showing total 11 results

Search Constraints

Start Over You searched for: Author "Eric Deconninck" Remove constraint Author: "Eric Deconninck"
11 results on '"Eric Deconninck"'

Search Results

1. R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS

2. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study

Catalog

Books, media, physical & digital resources

3. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma

4. Allogeneic Stem Cell Transplantation for Blast Crisis (BC) Chronic Myelogenous Leukemia (CML) In the Tyrosine Kinase Inhibitors (TKIs) Era. Analysis of Pre-Transplant Variables on Transplant Outcome. On Behalf of the Societe Française De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML

5. Updated Analysis of Allogeneic HSCT after RIC for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry

6. Impact of HLA Allele Mismatch on the Outcome of Patients with Reduced-Intensity Allogeneic Haematopoietic Stem Cell Transplantation from Unrelated Donors: Analysis of 103 Patients of the French Registry

7. Allogeneic Hematopoietic Stem Cell Transplantation Cures CLL: A Retrospective Analysis from the SFGM-TC Registry

8. Allogeneic Myelo-Ablative Stem Cell Transplant (SCT) as Salvage Therapy of Reduced-Intensity Conditioned (RIC) SCT: Toxicity and Outcome

9. Front-Line High-Dose Chemotherapy (HDT) Combined with Rituximab for Adults with Aggressive Large B-Cell Lymphoma (DLBCL) : Goelams 074 Trial

10. Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS

11. Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients